However, targeted systemic treatments for BC, particularly for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)-positive status [15], have improved survival for the metastatic disease over the past three decades [16]. This evidence concerns the gene ERBB2 and breast cancer.